

Sofosbuvir + velpatasvir

Essential medicine status

General description

A fixed-dose combination regimen of the direct acting antiviral agents sofosbuvir and velpatasvir for the treatment of genotypes 1-6 chronic hepatitis C virus (HCV) infection.

INN

Sofosbuvir + velpatasvir

ATC codes

[J05AP55](#)

Medicine type

Chemical agent

EML status history

First added in 2017 ([TRS 1006](#)) for [Chronic hepatitis C](#)

Wikipedia

[Sofosbuvir + velpatasvir](#)

DrugBank

[Sofosbuvir](#),

[Velpatasvir](#)

Recommendations

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 200 mg + 50 mg; 400 mg + 100 mg
- Oral > Solid > granules: 150 mg + 37.5 mg in sachet; 200 mg + 50 mg in sachet

Indications

[Chronic hepatitis C](#)